Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
¹ФГКУ «1586 военный клинический госпиталь» Минобороны РФ, Московская обл., г. Подольск, ул. Маштакова, тер. 4. ²ФГБУ МНИИП – филиал ФГБУ «НМИЦПН им. В.П. Сербского» МЗ РФ, г. Москва, ул. Потешная, д. 3. ³ГБСУ СО МО «Звенигородский психоневрологический интернат», г. Звенигород, Проезд Ветеранов, д. 6. ig.dorovskih@yandex.ru
Список исп. литературыСкрыть список 1. Sadock B.J., Sadock V.A., Ruiz P., Kaplan H.I. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 9th. / Philadelphia, Pa, USA: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2009. 4520 p. 2. American Psychiatric Association. Diagnositc and Statistical Manual of Mental Disorders / Arlington, Va, USA: American Psychiatric Association. 2013. 3. Khademvatan S., Saki J., Khajeddin N. et al. Toxoplasma gondii exposure and the risk of schizophrenia // Jundishapur Journal of Microbiology. 2014. Vol. 7, N.11:e12776. 4. Khademvatan S., Khajeddin N., Izadi S., Yousefi E. Investigation of anti- Toxocara and anti-Toxoplasma antibodies in patients with schizophrenia disorder // Schizophrenia Research and Treatment. 2014. Vol. 2014. 7 p. 5. Lau C.I., Wang H.C., Hsu J.L., Liu M.E. Does the dopamine hypothesis explain schizophrenia? // Rev. Neurosci. 2013. Vol. 24. P.389–400. 6. Hu W., MacDonald M.L., Elswick D.E., Sweet R.A. The glutamate hypothesis of schizophrenia: Evidence from human brain tissue studies // Ann. N.Y. Acad. Sci. 2015. Vol.1338. P.38–57. 7. Akhondzadeh S., Rezaei F., Larijani B. et al. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia // Schizophrenia Research. 2006. Vol. 84. Suppl. 2-3. P.405–410. 8. Ko Y.H., Jung S.W., Joe S.H. et al. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia // Psychoneuroendocrinology. 2007. Vol. 32. N. 4. P. 385– 391. 9. Shirayama Y., Hashimoto K., Suzuki Y., Higuchi T. Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia // Schizophrenia Research. 2002. Vol. 58. N. 1. P. 69–74. 10.Weiden P.J., Miller A.L. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications // J Psychiatr Pract. 2001. Vol. 7. P. 41–47. 11. Abraham G., Paing W.W., Kaminski J. et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study // Am J Psychiatry. 2003. Vol. 160. P. 1618–1620. 12. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects // Psychoneuroendocrinology. 2003. Vol. 28. N. 1. P.53–67. 13. Kishimoto T., Watanabe K., Shimada N. et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia // J Clin Psychiatry. 2008. Vol. 69. P. 385–391. 14.Wieck A., Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review // The British Journal of Psychiatry. 2003. Vol. 182. N. 3. P. 199–204. 15. Montejo A.L., Arango C., Bernardo M. et al. Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia // Revista de Psiquiatría y Salud Mental (English Edition). 2016. Vol. 9. N. 3. P. 158–173. 16. Montejo Á.L., Arango C., Bernardo M. et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics // Frontiers in Neuroendocrinology. 2017. Vol. 45. P. 25–34. 17. Vitiello B., Correll C., van Zwieten-Boot B. et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns // European Neuropsychopharmacology. 2009. Vol. 19. N. 9. P. 629–635. 18. Cookson J., Hodgson R., Wildgust H.J. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis // Journal of Psychopharmacology. 2012. Vol. 26. N. 5. P. 42–51. 19. Bahar A., Akha O., Kashi Z., Vesgari Z. Hyperprolactinemia in association with subclinical hypothyroidism // Caspian journal of internal medicine. 2011. Vol. 2. N. 2. P. 229. 20. La Torre D., Falorni A. Pharmacological causes of hyperprolactinemia // Therapeutics and Clinical Risk Management. 2007. Vol.3. N. 5. P.929. 21. Kim S., Park Y.M. Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study // PLoS One. 2013. Vol.8. N. 12:e82749. 22. Meltzer H.Y., Sachar E.J., Frantz A.G. Serum prolactin levels in unmedicated schizophrenic patients // Archives of General Psychiatry. 1974. Vol.31. N. 4. P. 564–569. 23. Muneyyirci-Delale O., Goldstein D., Reyes F.I. Diagnosis of stress-related hyperprolactinemia. Evaluation of the hyperprolactinemia rest test // New York state journal of medicine. 1989. Vol. 89. N. 4. P. 205–208. 24. Sonino N., Navarrini C., Ruini C. et al. Life events in the pathogenesis of hyperprolactinemia // European journal of endocrinology. 2004. Vol. 151. N. 1. P. 61–65. 25. Segal M., Avital A., Rojas M. et al. Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: a possible marker for the disease's subtypes // Psychiatry research. 2004. Vol. 127. N. 3. P. 227–235. 26. Garver D.L., Holcomb J.A., Christensen J.D. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum // The Journal of clinical psychiatry. 2000. Vol. 61. N. 12. P. 964–972. 27. Meaney A.M., O’Keane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia // Life Sci. 2002. Vol.71. N. 9. P. 979–992. 28. Hamner M.B., Arana G.W. Hyperprolactinaemia in antipsychotictreated patients. Guidelines for avoidance and management // CNS Drugs. 1998. Vol. 10. N. 3. P. 209–222. 29. Zhang-Wong J.H., Seeman M.V. Antipsychotic drugs, menstrual regularity and osteoporosis risk // Arch Womens Ment Health. 2002. Vol. 5. N. 3. P. 93–98. 30. Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis // J Psychopharmacol. 2008. Vol. 22. N. 2. P. 90–97. 31. Peuskens J. A literature review of «Prolactin in schizophrenia» // Clear perspectives: management issues in schizophrenia. 1997. Vol. 1, Issue 3. 42 p. 32. Rivera L., Lal S., Ettigi P. et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups // Clinical endocrinology. 1976. Vol. 5. N. 3. P. 273-282. 33. Naber D., C., Fischer B. et al. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms // Neuropsychobiology. 1980. Vol. 6. N. 4. P. 181-189. 34. Rao M.L., Brown W.A. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients // Psychopharmacology (Berl). 1987. Vol. 93. N. 2. P. 237-242. 35. Qijing Bo, Fang Dong, Xianbin Li et al. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia. // BMC Psychiatry. 2016. Vol. 16. P. 386. 36. Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review // CNS Drugs. 2014. Vol. 28. N. 5. P. 421–453. 37. Einarson T.R, Hemels M.E., Nuamah I. et al. An analysis of potentially prolactin- related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate // Ann Pharmacother. 2012. Vol. 46. N. 10. P.1322–1330. 38. Kleinberg D.L., Davis J.M., de Coster R. et al. Prolactin levels and adverse events in patients treated with risperidone // J Clin Psychopharmacol. 1999. Vol. 19. N. 1. P. 57–61. 39. Eberhard J., Lindstrom E., Holstad M. et al. Prolactin level during years of risperidone treatment in patients with psychotic disorders // Acta Psychiatr Scand. 2007. Vol. 115. N. 4. P. 268–276. 40. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia // Clin Pharm. 1992. Vol. 11. N. 10. P. 851–856. 41. Brown W.A., Laughren T.P. Tolerance to the prolactin-elevating effect of neuroleptics. // Psychiatry Res. 1981. Vol. 5. N. 3. P. 317–322. 42. Meltzer H.Y., Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients // Arch Gen Psychiatry.1976. Vol. 33. N. 3. P. 279– 286. 43. Meltzer H.Y., Fang V.S. Serum prolactin levels in schizophrenia – effect of antipsychotic drugs: a preliminary report / In: Sachar EJ, editor. Hormones, behaviour, and psychopathology. New York: Raven Press; 1976. P. 177–190. 44. Igarashi Y., Higuchi T., Toyoshima R. et al. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia // Adv Biochem Psychopharmacol. 1985. Vol. 40. P. 95–98. 45. Meltzer H.Y. Long-term effects of neuroleptic drugs on the neuroendocrine system // Adv Biochem Psychopharmacol. 1985. Vol. 40. P. 59–68. 46. Ahn Y.M., Lee K.Y, Kim C.E. et al. The acute and long-term effectiveness of amisulpride in patients with schizophrenia: of a 12-month open-label prospective follow-up study // Hum Psychopharmacol. 2011. Vol. 26. N. 8. P. 568–577. 47. Kim E.Y., Kim S.H., Lee N.Y. et al. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride // Pharmacopsychiatry. 2012. Vol. 45. N. 2. P. 57–63. 48. Dehelean L., Romosan A.M, Papava I. et al. Prolactin response to antipsychotics: An inpatient study // PLoS ONE. 2020. Vol. 15. N. 2: e0228648. 49. Kapur S., Zipursky R., Jones C. et al. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia // American Journal of Psychiatry. 2000. Vol. 157. N. 4. P. 514–520. 50. Gruen P.H., Sachar E.J., Langer G. et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects // Archives of General Psychiatry. 1978. Vol. 35. N. 1. P. 108–116. 51. Gruen P.H., Sachar E.J., Altman N. et al. Relation of plasma prolactin to clinical response in schizophrenic patients // Archives of general psychiatry. 1978. Vol. 35, N. 10. P. 1222–1227. 52. Zhang X.Y., Zhou D.F., Yuan C.L. et al. Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia // Psychiatry research. 2002. Vol. 109. N. 3. P. 297–302. 53. Faraone S.V., Brown W.A, Laughren T.P. Serum neuroleptic levels, prolactin levels, and relapse: a twoyear study of schizophrenic outpatients // The Journal of clinical psychiatry. 1987. Vol. 48. P. 151–154. 54. Brown W.A. Neuroleptics and Prolactin / In Psychoneuroendocrine Dysfunction. Springer, Boston, MA. 1984. P. 569–582. 55. Tandon R., Mazzara C., DeQuardo J. et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. // Biological Psychiatry. 1991. Vol. 29. N. 10. P. 953–964. 56. Pariante C.M., Vassilopoulou K., Velakoulis D. et al. Pituitary volume in psychosis. The // British Journal of Psychiatry. 2004. Vol. 185. N. 1. P. 5– 10. 57. Lum C., Kucharczyk W., Montanera W.J., Becker L.E. The sella turcica and parasellar region / Magnetic Resonance Imaging of the Brain and Spine. Lippincott, Williams and Wilkins: Philadelphia. 2002. P. 1283–1362. 58. Karoum F., Karson C.N., Bigelow L.B. et al. Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia // Archives of General Psychiatry. 1987. Vol. 44. N. 7. P. 604–607. 59. Lieberman J.A., Alvir J.M., Koreen A. et al. Psychobiologic correlates of treatment response in schizophrenia // Neuropsychopharmacology. 1996. Vol. 14. N. 3. P. 13–21. 60. Naber D., Mueller F. Effects of Long-Term Neuroleptic Treatment on Serum Levels of Prolactin, TSH, LH, and Norepinephrine and on α-Adrenergic and Dopaminergic Receptor Sensitivity / In Psychoneuroendocrine Dysfunction. Springer, Boston, MA. 1984. P. 599–612. 61. Hayes E., Gavrilidis E., Kulkarni J. The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia // Schizophrenia Research and Treatment. 2012. Vol. 2012. 8 p.